Answers are grounded in this paper and cite their sources.
Preclinical screening identifies esaxerenone as a phenotypic hit in polycystic kidney disease models, suggesting novel therapeutic targets for further confirmation.
AR-linked hypothesis and identified Esaxerenone as a compound-specific phenotypic hit; both require mechanistic confirmation and evaluation in additional disease models.
No takes yet. Share an insight, caveat, or question.
Araripe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: